H&H國際控股(01112.HK)一季度收入升13.0%至24.24億元 中國市場收入佔比達81.6%
格隆匯5月8日丨H&H國際控股(01112.HK)披露截至2020年3月31日止3個月的未經審核營運數據。儘管第一季度面臨2019新冠肺炎的挑戰，但收入仍較去年同期增長13.0%至人民幣24.237億元，主要貢獻來自於中國市場兩個業務分部強勁的業績表現。
截至2020年3月31日止3個月，來自中國的收入受國內嬰幼兒營養及護理用品以及成人營養及護理用品業務的雙位數增長支持，實現同比增長19.4%，目前中國市場佔集團總收入的81.6%，去年同期則為77.2%。該增長有賴中國消費者對高端營養及護理用品的需求持續強勁，加上集團於2019新冠肺炎疫情初期採取預防性措施，令集團得以維持正常營運並克服短暫業務干擾。
截至2020年3月31日止3個月，因2019新冠肺炎疫情導致的旅行限制使代購商在短期內面臨進一步挑戰，然而市場當地需求保持穩定，因此來自澳新市場的收入按同類比較基準按年下降8.5%。目前，集團於澳洲製造的保健品及嬰幼兒配方羊奶粉生產並未面臨任何中斷。截至2020年3月31日止12個月，Swisse於澳洲維生素、草本及礦物補充劑市場的份額達致14.7%5。
截至2020年3月31日止3個月，其他海外市場收入同比下降9.1%，主要由於中國香港市場在2019新冠肺炎疫情下的銷售下跌所致。儘管如此，集團的嬰幼兒配方奶粉、嬰幼兒食品系列及免疫力相關產品在荷蘭、意大利、法國及英國維持穩健增長勢頭。集團繼續按計劃在新市場推出產品：目前已在印度的亞馬遜及其他10多個主要電子商務平台推出Swisse產品，同時在新加坡的線上及線下渠道推出Biostime的益生菌系列。
得益於剛需的產品組合及靈活的商業模式，集團於截至2020年3月31日止3個月產生正面現金流量並維持充裕的流動資金。作為應對市場波動的預防措施，集團於三月提取循環信貸融資中的5000萬美元，以建立額外的流動資金緩衝。截至2020年3月31日，集團的現金結餘為人民幣30.8億元，較去年同期的人民幣22.2億元增加人民幣8.6億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
